Pharma & Biotech News #PharmaBuzz

Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

Weekly News Recap #Phispers

Lilly buys three vaccine drugmakers in deals worth up to US$ 3.8 bn; FDA approves AbbVie's ultra rare blood cancer drug

Buoyed by the rising sales of its obesity drug, Eli Lilly has been on an acquisition spree this year. The company announced ag...

Impressions : 1266

FDA issues warning letter to Chinese supplier of semaglutide; approves AstraZeneca's new treatment for hypertension

In Phispers this week, the US Food and Drug Administration (FDA) approved AstraZeneca’s first-in-class treatment for hype...

Impressions : 2128

FDA chief Marty Makary resigns after rocky tenure; Italy's Angelini to buy Catalyst Pharma for US$ 4.1 billion

The US Food and Drug Administration (FDA) has seen several high profile exits under the Trump Administration. The most high pro...

Impressions : 1565

FDA issues warning letter to Intas' plant in north India; okays Axsome's drug for Alzheimer's-related agitation

In Phispers this week, India’s Intas Pharmaceuticals received a warning letter from the US Food and Drug Administration (...

Impressions : 1986

Only few entries up to this point, click to access all

Quality Compliance Alerts #Warning!

All News #Library

Generics

Biotech

APIs

Quality

Sciences

Rare Diseases

Others

NEWS

DRUGS & DEVELOPMENTS

MARKET INTEL by PharmaCompass

Lilly buys three vaccine drugmakers in deals worth up to US$ 3.8 bn; FDA approves AbbVie's ultra rare blood cancer drug

FDA issues warning letter to Chinese supplier of semaglutide; approves AstraZeneca's new treatment for hypertension

FDA chief Marty Makary resigns after rocky tenure; Italy's Angelini to buy Catalyst Pharma for US$ 4.1 billion

FDA issues warning letter to Intas' plant in north India; okays Axsome's drug for Alzheimer's-related agitation

Galderma 's Differin Epiduo Acne Gel Receives Approval in US

Gilead's Biologics Hepcludex Receives Approval in US

Mankind's Generics Sitagliptin Receives Tentative Approval in US

Steran Hlthcare's Generics Lacosamide Receives Approval in US

Rubin Research's Generics Clonazepam Receives Approval in US

Aurobindo's Generics Empagliflozin Receives Approval in US

MSN's Generics Acalabrutinib Receives Tentative Approval in US

Alembic's Generics Levothyroxine Na Receives Approval in US

Micro's Generics Mirtazapine Receives Approval in US

Actavis's Generics Linaclotide Receives Tentative Approval in US

Alchymars ICM SM's Receives FDA Warning Letter

GC America's Receives FDA Warning Letter

Sato's Receives FDA Warning Letter

Enforcement Report - Week of May 20, 2026

Alchymars ICM SM Private Limited is on FDA Import Alert List

Hangzhou Yiqi Biotechnology's Receives FDA Warning Letter

Naseem A Jaffrani's Receives FDA Warning Letter

Sourav K Mishra's Receives FDA Warning Letter

JW Nutritional's Receives FDA Warning Letter

Best Supplements Recalls WAP Capsules for Undeclared Active Drugs

Molecule Glue Drugs Shake Up Cancer Care, Draw Big Money

Samsung Bioepis Launches OPUVIZ Aflibercept Vial in Europe

Wockhardt Gets CDSCO Nod for Zaynich Antibiotic

Supriya Lifescience posts 50% revenue growth in Q4 FY26

Innovent Biologics, Pfizer Enter Global Oncology Collaboration

FDA OKs TREMFYA: Only IL-23 Proven to Stop Joint Damage

GSK's Hepatitis B Drug Helps One in Five Achieve Functional Cure

Cipla's MD & Group CEO Foresees Growth Driven By Innovation

AstraZeneca Gains 2nd Bladder Cancer Nod for Imfinzi

The $13 Million Company Teaching the Immune System to Hunt Cancer

Felix Offers Ozempic at Generic-Level Pricing in Canada

GoodRx Launches Subscription to Lower Healthcare Costs

Ionetix Gets ANDA Approval for Ga-68 Gozetotide (PSMA-11)

Brazil Approves First Generic Version of Ozempic

Jubilant Pharmova Posts FY26 Revenue Of Rs. 8,280 Crore, Up 14%

Alembic Gets USFDA Nod For Generic Levothyroxine Sodium Tablets

Hims & Hers Launches Generic Semaglutide in Canada

Takeda Pharma Ordered To Pay $2.5 Billion In Amitiza Case

Sunshine Biopharma Gets Canadian OK for Generic Amoxicillin

MedExpress Canada Launches Generic Semaglutide At $124.99

Molecule Glue Drugs Shake Up Cancer Care, Draw Big Money

Samsung Bioepis Launches OPUVIZ Aflibercept Vial in Europe

Innovent Biologics, Pfizer Enter Global Oncology Collaboration

FDA OKs TREMFYA: Only IL-23 Proven to Stop Joint Damage

GSK's Hepatitis B Drug Helps One in Five Achieve Functional Cure

AstraZeneca Gains 2nd Bladder Cancer Nod for Imfinzi

The $13 Million Company Teaching the Immune System to Hunt Cancer

Arvinas To Present At Jefferies Global Healthcare Conference

Replimune Will Again Submit Its Melanoma Drug For Approval

Kane Biotech Announces Grant Of Stock Options

Wockhardt Gets CDSCO Nod for Zaynich Antibiotic

CordenPharma Strikes Peptide CDMO Deal for US and China Sites

True North Buys 25% Stake In Pharma co Embio

Why Choosing the Right Mupirocin Calcium Manufacturer Matters

Gilead Inks $140M Deal With Korean API Maker Yuhan

FDA: 17 Drugs Approved via Continuous Manufacturing

Curia Completes API Aseptic Suite Upgrade in Valladolid, Spain

BioNxt Advances Semaglutide ODF into Active Pharma Development

Bulk Drugs And Intermediates Exports Grew 3.76% In FY26

Drugmakers Battle Rising Costs, Export Slump

NPPA Fixes Retail Prices Of 30 New Drugs

Insulet Issues Voluntary Correction for Leaky Omnipod Devices

Coal Minister Flags Unregulated Expansion Of Online Pharmacies

Biogen Investigated by Regulator Over MS 'market Abuse' Claims

KPRDO Demands Ban on Misleading Pharma Ads & Enforcement Team

Strong Oversight Anchors India's Surging Global Pharma Footprint

FDA Issues GMP Warnings to Drugmakers in US Japan & India

Aurobindo Telangana facility gets OAI classification from FDA

SEC Recommends Discontinuation of Crizanlizumab Import Permission

Strides Pharma Gets 5 FDA Observations After Bengaluru Audit

Spectral Medical Announces PMA Submission To U.S. FDA For PMX

Study Finds Low PCCP Utilization Among Ai-Enabled Devices

NeuLogiq Platform Confirms No Psychotomimetic Effects in Phase 1b